Add Row
Add Element
cropper
update
Ai Pulth
Ai Pulse Health
update
Add Element
  • Home
  • Categories
    • Better Patient Care
    • New Medical Discoveries
    • Smart Health Tools
    • AI and Ethics
    • Real-Life Success Stories
    • What’s Next in AI Health
Add Row
Add Element
June 10.2025
3 Minutes Read

Health Professionals Voice Outrage Over HHS Dismissing ACIP Members

Stylized healthcare presentation on vaccine, sleek silhouette figures.

The Outcry Over ACIP Dismissals: A Call for Trust in Vaccines

The recent decision to fire all 17 members of the CDC’s Advisory Committee on Immunization Practices (ACIP) has prompted a wave of indignation among health professionals and organizations nationwide. As Robert F. Kennedy, Jr., Secretary of the U.S. Department of Health and Human Services (HHS), seeks to completely overhaul the committee, concerns regarding public trust in vaccines are mounting. Health experts fear that this shake-up could undermine years of careful scientific evaluation and negatively impact public health.

Why Were ACIP Members Fired?

Kennedy justified these drastic measures in a Wall Street Journal opinion piece, claiming that the previous ACIP members possessed conflicts of interest and were unduly influenced by vaccine manufacturers. With COVID-19 and other vaccination strategies in disarray, his push for a 'clean sweep' was framed as a necessary move to regain public confidence. However, critics argue that such a fundamental shift could create confusion rather than clarity.

Healthcare Professionals Respond: A Unified Outrage

Prominent health leaders have voiced their alarm at Kennedy's actions. Dr. Susan Kressly, President of the American Academy of Pediatrics, expressed her deep concern and labeled the firings as part of a broader strategy to undermine established medical expertise and foster distrust in lifesaving vaccinations. This view is echoed by Dr. Georges C. Benjamin, Executive Director of the American Public Health Association, who described Kennedy’s maneuver as a 'coup.' He emphasized that the fired members were some of the most qualified individuals to evaluate vaccine safety and efficacy.

Potential Ramifications for Public Health

The repercussions of the ACIP reconstitution are not to be taken lightly. Dr. Jason Goldman, President of the American College of Physicians, highlighted the risks that stem from circumventing established protocols for vaccine evaluation. He warned that undermining trust in expert guidance during critical vaccination campaigns could stifle patient engagement and worsen public health outcomes.

Voices from Congress: Concerns About Future Direction

Their worries reached even the halls of Congress. Senator Bill Cassidy expressed trepidation that Kennedy may appoint individuals lacking real expertise in immunization. Meanwhile, Congresswoman Kim Schrier cautioned that this could pave the way for non-experts to dominate ACIP, potentially leading to unfounded recommendations that collide with scientific consensus.

Restoring Confidence in Vaccines

As we grapple with these looming changes, the challenge remains: How can we restore public trust in vaccines? Health organizations advocate for transparency and accountability in any new appointments to the ACIP. Additionally, they stress the importance of returning to science-driven policies that consider the well-being of the greater public.

Next Steps and Community Involvement

The fate of the vaccination protocol in a post-firing era hinges on community involvement. The calls for public discourse surrounding these policy changes cannot be ignored. Health-conscious individuals, caregivers, and medical professionals are encouraged to voice their concerns and expectations moving forward. Action can take the shape of attending town hall meetings, contacting their representatives, or actively participating in public health forums.

Conclusion: Emphasizing Our Shared Responsibility

With the backdrop of these unsettling developments, it is imperative to remind ourselves of our shared responsibility for promoting health and wellness in our communities. An empowered and educated public can make a significant difference. So join the conversation, ask questions, and demand clarity and accountability. Only together can we safeguard a future where vaccines remain trusted tools for public health.

By sharing your thoughts and staying informed about healthcare policies, you contribute to a more robust fight against misinformation and enhance patient wellness strategies that serve us all. Stay engaged, stay informed, and advocate for the science that keeps us healthy.

Better Patient Care

0 Views

0 Comments

Write A Comment

*
*
Related Posts All Posts
06.17.2025

Asciminib: Transforming Second-Line CML Treatment with High Response Rates

Update Asciminib: A New Hope for Chronic Myeloid Leukemia Patients In an exciting development for patients battling chronic myeloid leukemia (CML), asciminib, a groundbreaking treatment, has shown promising results as a second-line therapy. As the first drug of its kind to target the BCR-ABL1 mutant protein effectively, asciminib's dose-escalation approach offers hope for those who haven’t achieved optimal responses with earlier treatments. A recent study, involving over 100 participants across 85 trial sites in the United States, confirms that this innovative therapy could be a game-changer for many. Understanding the Study and Its Results The interim analysis uncovered some fascinating insights: approximately 44.4% of patients achieved a major molecular response by week 24, while 25.4% reached a deep molecular response. Importantly, these positive outcomes occurred even among people who had previously discontinued treatments due to inefficacy or intolerance. The study involved a flexible dosing regimen, adjusting from 80 mg to 200 mg daily based on the BCR-ABL levels, showcasing the tailored approach in managing chronic disease. Safety Profile: An Essential Consideration Another reassuring aspect of the asciminib findings is its safety profile, which appears consistent with previous studies. Most patients tolerated the drug well, with only a few serious adverse events reported, including hypertension and thrombocytopenia. This level of tolerance is crucial, especially for patients who have faced earlier treatment challenges, reflecting a significant improvement in CML management. Understanding the balance between efficacy and safety is vital for healthcare professionals and patients alike. The Mechanism Behind Asciminib's Success Unlike existing therapies that primarily focus on competitive inhibition of BCR-ABL1, asciminib uniquely targets the myristoyl pocket of the ABL protein. This innovative mechanism not only enhances its effectiveness but also minimizes off-target effects. As Dr. David Jacob Andorsky notes, this specificity could lead to better patient outcomes in chronic-phase CML, setting asciminib apart from conventional TKIs. Implications for Patient Care and Future Research The implications of these findings extend beyond individual treatment regimens. Healthcare providers can integrate asciminib into personalized healthcare solutions tailored to each patient’s needs. As chronic disease management evolves, the role of AI in healthcare also begins to shine through. With ongoing analysis and future investigations planned, asciminib may pave the way for new treatment protocols and enhanced patient care strategies in hematology. Empowering Patients with Knowledge As promising as these results are, it’s vital for patients and caregivers to stay informed about treatment innovations. Understanding mediations like asciminib helps empower individuals to engage actively in their healthcare decisions. This proactive approach to health management is essential, especially in fields as complex as oncology. Conclusion: A Call to Action As we witness advancements in treatment options such as asciminib, it's crucial for patients, caregivers, and healthcare professionals to remain informed. Sharing insights from ongoing research can facilitate better patient outcomes and enhance the quality of care offered. If you or someone you know is navigating chronic-phase CML, consider discussing these novel options with healthcare providers for a more informed path forward.

06.17.2025

Elevidys Gene Therapy Suspended After Patient Deaths: What You Need to Know for DMD Care

Update Understanding the Risks of DMD Gene Therapy: Two Patient Deaths Shock the CommunityThe recent suspension of the gene therapy Elevidys has shaken the DMD (Duchenne muscular dystrophy) community. Sarepta Therapeutics made this decision after two separate instances of acute liver failure led to patient fatalities following treatment. The first case was reported in March 2025, involving a teenage boy, and just weeks later, another tragedy prompted a deeper examination of the therapy's implications and safety. This has raised vital questions about the efficacy and safety of gene therapies designed to combat rare genetic diseases.The Role of Regulatory Oversight in Patient SafetyThe deaths have led to an immediate pause in shipments of Elevidys for non-ambulatory patients, highlighting the critical role of regulatory bodies in ensuring patient safety. As stated by the company, enhanced protocols are set to be evaluated in collaboration with health authorities while existing patients are monitored under current treatment guidelines. Sarepta's plan to amend its immunosuppressive regimen is a responsive measure aiming to enhance patient outcomes, underscoring the importance of adapting new therapies in the face of unforeseen challenges.Future Implications for Gene Therapy and DMD TreatmentsThe halted study on Elevidys, particularly in the ENVISION trial—a pivotal clinical trial assessing its efficacy—is expected to have widespread implications for how gene therapies are approached in the future. The FDA’s expedited review process previously granted the treatment accelerated approval, but the tragic outcomes may necessitate a more stringent scrutiny going forward. As gene therapy evolves, so too must our understanding of biological responses, particularly in populations with limited therapeutic options like those affected by DMD.The Emotional Impact on Patients and FamiliesFor families navigating the complexities of DMD, the news of these deaths is a sober reminder of the delicate balance between advancing medical technology and ensuring patient wellbeing. Coping with the uncertainty surrounding treatment options can be emotionally taxing. Caregivers play a pivotal role in providing support and navigating the powerful emotional landscape that accompanies chronic illnesses. Resources, emotional support networks, and open lines of communication with healthcare providers become even more vital during such unsettling times.Patient Care Innovations: Learning from SetbacksDespite the unfortunate outcomes associated with Elevidys, there remains a realm of hope for ongoing advancements in gene therapy and overall health management for DMD and other chronic conditions. Innovations in patient monitoring, enhanced telemedicine solutions, and personalized healthcare plans are crucial in addressing treatment gaps. The use of AI in healthcare is paving the way for improved patient wellness strategies, offering the promise of real-time insights and smarter patient care management.Adapting to Changes: What Patients Can DoFor families of non-ambulatory DMD patients, this situation underscores the necessity of routine check-ups and open discussions with healthcare professionals. Monitoring overall health, being educated about emerging therapies, and engaging in supportive communities can empower families during turbulent times. It is essential to stay informed about treatment options and to not hesitate in seeking second opinions, as patient autonomy remains paramount.The Future of DMD Treatments: Hope Amid UncertaintyAs the healthcare landscape evolves, those impacted by DMD are reminded that innovation is often accompanied by challenges. The suspension of Elevidys may shed light on necessary improvements that can be made to ensure patient safety. The ongoing quest for more effective therapies should not only look to groundbreaking science but also ensure that the human aspect of healthcare—safety, compassion, and understanding—remains at the forefront. Future communication from healthcare providers and companies like Sarepta will be crucial in setting the stage for renewed confidence in emerging therapies.

06.16.2025

Understanding Timeliness in MI Treatment: Critical Insights for Patients and Caregivers

Update Delays in MI Treatment: A Growing Concern Timeliness in medical interventions can dramatically influence patient outcomes, especially for those experiencing a myocardial infarction (MI). Unfortunately, recent research highlights that several hospitals are falling short of the national guidelines for treating acute ST-elevation MI (STEMI), which could lead to increased mortality rates. This analysis brings to light the criticality of addressing treatment delays that arise within hospital systems and not just from patient-related factors. The Data Behind the Delays A retrospective study led by Dr. Neal S. Kleiman of the Houston Methodist DeBakey Heart and Vascular Center examined the treatment times of 73,826 patients suffering from STEMI. An alarming finding was that, often, hospitals were not meeting the benchmark of delivering percutaneous coronary intervention (PCI) within 90 minutes of the initial medical contact. In fact, low-performing hospitals showed a twofold increase in in-hospital mortality rates compared to high-performing hospitals. This disparity underscores the importance of examining how hospitals can improve their operational efficiency. The Urgency of Prompt Care The guidelines stipulate that first medical contact should ideally lead to angioplasty with stenting in under 90 minutes, and for patients needing transfer, the timeframe extends to 120 minutes. Yet, the study revealed disheartening statistics: only 72.2% of patients at high-performing sites met the 90-minute target, while low-performing sites only managed 46.0%. For patients requiring transfer, compliant hospitals managed just 21.9% within the recommended timeframe. Understanding Patient vs. System-Centered Delays Dr. Kleiman pointed out that there are two types of delays when it comes to treatment: those that are patient-centered and those that stem from system failures. As caregivers and healthcare advocates, it’s vital we address the preventable delays caused by hospital systems, such as lengthy emergency department stays and bottlenecks that hinder timely care. Improving hospital protocols could easily streamline the process, saving lives in the process. Insights for Better Patient Care As healthcare shifts more towards patient empowerment and technology-driven solutions, understanding these delays could lead to impactful changes. Healthcare providers and patients alike should advocate for systems that prioritize timely intervention. The shift towards AI-driven healthcare solutions and smart health monitoring is an essential step in ensuring patients receive timely treatments, thus improving overall health outcomes. Future of Healthcare and the Role of Technology Investing in healthcare technology trends can significantly decrease treatment delays. For instance, integrating telemedicine updates can facilitate faster diagnostic processes, while AI-driven patient monitoring can predict potential emergencies before they manifest. These innovations not only speed up treatment times but also enhance the quality of care provided to patients. Patients can adopt personal wellness strategies and engage in preventive healthcare tips, ensuring they are proactive about their health. Empowering Patients Through Knowledge Understanding the urgency surrounding timely treatment for MI is not just for healthcare providers; it also empowers patients and their families to advocate for better care. Being aware of hospital performance metrics and expected treatment timelines can better prepare patients during emergencies. Knowledge is power, and with the right information, patients can contribute to their wellness journey and demand improvements in healthcare systems. Implementing Changes Now Healthcare advancements hinge on continuous learning and adaptation. To truly improve patient outcomes regarding myocardial infarction treatment, healthcare systems need to implement actionable insights from studies like Dr. Kleiman’s. Emphasizing better organization within hospitals can dramatically decrease in-hospital mortality rates for MI patients. Encouraging patients to be aware of their treatment options and timelines could also serve as a cornerstone for better care experiences. Conclusion: Take Action for Better Outcomes The insights provided by this research can lead to significant shifts in how healthcare is approached, not only improving outcomes for patients experiencing MIs but also fostering a healthier overall community. Let's advocate for change in healthcare performance metrics and push for timely interventions, ensuring that every individual gets the urgent care they need.

Add Row
Add Element
Ai Pulse Health
UPDATE
Add Element
  • update
  • update
  • update
  • update
  • update
  • update
  • update
Add Element

ABOUT US

AI Pulse Health delivers the latest news and insights on how AI is transforming healthcare, from medical advancements to wellness tools and patient care innovations.

Add Element
Add Element

© 2025 Ai Pulse Health All Rights Reserved. Harp Island Close, London, Brent NW100DF . Contact Us . Terms of Service . Privacy Policy

{"company":"Ai Pulse Health","address":"Harp Island Close","city":"London","state":"Brent","zip":"NW100DF","email":"lorenas@getmilerismarketing.com","tos":"PHA+PHN0cm9uZz48ZW0+V2hlbiB5b3Ugc2lnbi1pbiB3aXRoIHVzLCB5b3UgYXJlIGdpdmluZyZuYnNwOyB5b3VyIHBlcm1pc3Npb24gYW5kIGNvbnNlbnQgdG8gc2VuZCB5b3UgZW1haWwgYW5kL29yIFNNUyB0ZXh0IG1lc3NhZ2VzLiBCeSBjaGVja2luZyB0aGUgVGVybXMgYW5kIENvbmRpdGlvbnMgYm94IGFuZCBieSBzaWduaW5nIGluIHlvdSBhdXRvbWF0aWNhbGx5IGNvbmZpcm0gdGhhdCB5b3UgYWNjZXB0IGFsbCB0ZXJtcyBpbiB0aGlzIGFncmVlbWVudC48L2VtPjwvc3Ryb25nPjwvcD4KCjxwPjxhIGhyZWY9Imh0dHA6Ly93d3cuZ29vZ2xlLmNvbSI+aHR0cDovL3d3dy5nb29nbGUuY29tPC9hPjwvcD4KCjxwPiZuYnNwOzwvcD4KCjxwPjxzdHJvbmc+U0VSVklDRTwvc3Ryb25nPjwvcD4KCjxwPldlIHByb3ZpZGUgYSBzZXJ2aWNlIHRoYXQgY3VycmVudGx5IGFsbG93cyB5b3UgdG8gcmVjZWl2ZSByZXF1ZXN0cyBmb3IgZmVlZGJhY2ssIGNvbXBhbnkgaW5mb3JtYXRpb24sIHByb21vdGlvbmFsIGluZm9ybWF0aW9uLCBjb21wYW55IGFsZXJ0cywgY291cG9ucywgZGlzY291bnRzIGFuZCBvdGhlciBub3RpZmljYXRpb25zIHRvIHlvdXIgZW1haWwgYWRkcmVzcyBhbmQvb3IgY2VsbHVsYXIgcGhvbmUgb3IgZGV2aWNlLiBZb3UgdW5kZXJzdGFuZCBhbmQgYWdyZWUgdGhhdCB0aGUgU2VydmljZSBpcyBwcm92aWRlZCAmcXVvdDtBUy1JUyZxdW90OyBhbmQgdGhhdCB3ZSBhc3N1bWUgbm8gcmVzcG9uc2liaWxpdHkgZm9yIHRoZSB0aW1lbGluZXNzLCBkZWxldGlvbiwgbWlzLWRlbGl2ZXJ5IG9yIGZhaWx1cmUgdG8gc3RvcmUgYW55IHVzZXIgY29tbXVuaWNhdGlvbnMgb3IgcGVyc29uYWxpemF0aW9uIHNldHRpbmdzLjwvcD4KCjxwPllvdSBhcmUgcmVzcG9uc2libGUgZm9yIG9idGFpbmluZyBhY2Nlc3MgdG8gdGhlIFNlcnZpY2UsIGFuZCB0aGF0IGFjY2VzcyBtYXkgaW52b2x2ZSB0aGlyZC1wYXJ0eSBmZWVzIChzdWNoIGFzIFNNUyB0ZXh0IG1lc3NhZ2VzLCBJbnRlcm5ldCBzZXJ2aWNlIHByb3ZpZGVyIG9yIGNlbGx1bGFyIGFpcnRpbWUgY2hhcmdlcykuIFlvdSBhcmUgcmVzcG9uc2libGUgZm9yIHRob3NlIGZlZXMsIGluY2x1ZGluZyB0aG9zZSBmZWVzIGFzc29jaWF0ZWQgd2l0aCB0aGUgZGlzcGxheSBvciBkZWxpdmVyeSBvZiBlYWNoIFNNUyB0ZXh0IG1lc3NhZ2Ugd2Ugc2VuZCB0byB5b3UuIEluIGFkZGl0aW9uLCB5b3UgbXVzdCBwcm92aWRlIGFuZCBhcmUgcmVzcG9uc2libGUgZm9yIGFsbCBlcXVpcG1lbnQgbmVjZXNzYXJ5IHRvIGFjY2VzcyB0aGUgU2VydmljZSBhbmQgcmVjZWl2ZSB0aGUgU01TIHRleHQgbWVzc2FnZXMuIFdlIGRvIG5vdCBjaGFyZ2UgYW55IGZlZXMgZm9yIHRoZSBkZWxpdmVyeSBvZiBlbWFpbCBvciBTTVMuIFRoaXMgaXMgYSBmcmVlIHNlcnZpY2Ugd2UgcHJvdmlkZS4gSG93ZXZlciwgcGxlYXNlIGNoZWNrIHdpdGggeW91ciBpbnRlcm5ldCBzZXJ2aWNlIHByb3ZpZGVyIGFuZCBjZWxsdWxhciBjYXJyaWVyIGZvciBhbnkgY2hhcmdlcyB0aGF0IHlvdSBtYXkgaW5jdXIgYXMgYSByZXN1bHQgb2YgcmVjZWl2aW5nIGVtYWlsIGFuZCBTTVMgdGV4dCBtZXNzYWdlcyB0aGF0IHdlIGRlbGl2ZXIgdXBvbiB5b3VyIG9wdC1pbiBhbmQgcmVnaXN0cmF0aW9uIHdpdGggb3VyIGVtYWlsIGFuZCBTTVMgc2VydmljZXMuIFlvdSBjYW4gY2FuY2VsIGF0IGFueSB0aW1lLiBKdXN0IHRleHQgJnF1b3Q7U1RPUCZxdW90OyB0byZuYnNwOzxoaWdobGlnaHQgY2xhc3M9ImNvbXBhbnlTTVNQaG9uZVVwZGF0ZSI+bnVsbDwvaGlnaGxpZ2h0Pi4gQWZ0ZXIgeW91IHNlbmQgdGhlIFNNUyBtZXNzYWdlICZxdW90O1NUT1AmcXVvdDsgdG8gdXMsIHdlIHdpbGwgc2VuZCB5b3UgYW4gU01TIG1lc3NhZ2UgdG8gY29uZmlybSB0aGF0IHlvdSBoYXZlIGJlZW4gdW5zdWJzY3JpYmVkLiBBZnRlciB0aGlzLCB5b3Ugd2lsbCBubyBsb25nZXIgcmVjZWl2ZSBTTVMgbWVzc2FnZXMgZnJvbSB1cy48L3A+Cgo8cD48c3Ryb25nPllPVVIgUkVHSVNUUkFUSU9OIE9CTElHQVRJT05TPC9zdHJvbmc+PC9wPgoKPHA+SW4gY29uc2lkZXJhdGlvbiBvZiB5b3VyIHVzZSBvZiB0aGUgU2VydmljZSwgeW91IGFncmVlIHRvOjwvcD4KCjxvbD4KCTxsaT5wcm92aWRlIHRydWUsIGFjY3VyYXRlLCBjdXJyZW50IGFuZCBjb21wbGV0ZSBpbmZvcm1hdGlvbiBhYm91dCB5b3Vyc2VsZiBhcyBwcm9tcHRlZCBieSB0aGUgU2VydmljZSYjMzk7cyByZWdpc3RyYXRpb24gZm9ybSAoc3VjaCBpbmZvcm1hdGlvbiBiZWluZyB0aGUgJnF1b3Q7UmVnaXN0cmF0aW9uIERhdGEmcXVvdDspIGFuZDwvbGk+Cgk8bGk+bWFpbnRhaW4gYW5kIHByb21wdGx5IHVwZGF0ZSB0aGUgUmVnaXN0cmF0aW9uIERhdGEgdG8ga2VlcCBpdCB0cnVlLCBhY2N1cmF0ZSwgY3VycmVudCBhbmQgY29tcGxldGUuIElmIHlvdSBwcm92aWRlIGFueSBpbmZvcm1hdGlvbiB0aGF0IGlzIHVudHJ1ZSwgaW5hY2N1cmF0ZSwgbm90IGN1cnJlbnQgb3IgaW5jb21wbGV0ZSwgb3Igd2UgaGF2ZSByZWFzb25hYmxlIGdyb3VuZHMgdG8gc3VzcGVjdCB0aGF0IHN1Y2ggaW5mb3JtYXRpb24gaXMgdW50cnVlLCBpbmFjY3VyYXRlLCBub3QgY3VycmVudCBvciBpbmNvbXBsZXRlLCB3ZSBoYXZlIHRoZSByaWdodCB0byBzdXNwZW5kIG9yIDxzdHJvbmc+PHNwYW4gc3R5bGU9ImNvbG9yOiNGRjAwMDA7Ij50ZXJtaW5hdGUgeW91ciBhY2NvdW50L3Byb2ZpbGUgYW5kIHJlZnVzZSBhbnkgYW5kIGFsbCBjdXJyZW50IG9yIGZ1dHVyZSB1c2Ugb2YgdGhlIFNlcnZpY2UgKG9yIGFueSBwb3J0aW9uIHRoZXJlb2YpLjwvc3Bhbj48L3N0cm9uZz48L2xpPgo8L29sPgoKPHA+Jm5ic3A7PC9wPgo8aGlnaGxpZ2h0IGNsYXNzPSJjb21wYW55TmFtZVVwZGF0ZSI+QWkgUHVsc2UgSGVhbHRoPC9oaWdobGlnaHQ+PGJyIC8+CjxoaWdobGlnaHQgY2xhc3M9ImNvbXBhbnlBZGRyZXNzVXBkYXRlIj5IYXJwIElzbGFuZCBDbG9zZSwgTG9uZG9uLCBCcmVudCBOVzEwMERGPC9oaWdobGlnaHQ+PGJyIC8+CjxoaWdobGlnaHQgY2xhc3M9ImNvbXBhbnlQaG9uZVVwZGF0ZSI+KzQ0Nzg1NjU1MDAzNTwvaGlnaGxpZ2h0PjxiciAvPgo8aGlnaGxpZ2h0IGNsYXNzPSJjb21wYW55RW1haWxVcGRhdGUiPmxvcmVuYXNAZ2V0bWlsZXJpc21hcmtldGluZy5jb208L2hpZ2hsaWdodD4=","privacy":"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"}

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*